Conversely, although HER2-low evolution was less frequently observed in our triple-negative cohort than the HR-positive one, almost 30% of triple-negative breast cancer patients exhibited a conversion either from or to HER2-low expression. Here, ERBB2 is linked to triple-negative breast carcinoma.